

Covid-19 Vaccines Approved in Canada: mRNA vaccines

Individuals who started their primary series with the original monovalent or bivalent vaccines can complete their primary series with the updated XBB.1.5 formulation.

Regardless of which product was used to start a primary series, the previous dose(s) should be counted and the series need not be restarted.

COMIRNATY* (Pfizer) COMIRNATY* (Pfizer) Omicron XBB.1.5 Om	Regulatess of which product was used to start a primary series, the previous dose(s) should be counted and the series need not be restarted.										
Vaccine Type MRNA Monovalent Multidose (0.012 manulations Multidose (0.012 manulations Multidose (0.012 manulations Multidose (0.012 manulations Multidose (0.01		Moderna (Spikevax™)		COMIRNATY® (Pfizer)	COMIRNATY® (Pfizer)	COMIRNATY®(Pfizer)					
Royal Blue cap Coral Blue label Colour Coral Blue label Colour Coral Blue label Colour Maroon label border Maroon label border Blue label border Grey label boarder Grey label boarder Grey label boarder Multidose (0.10 mg/ml) (0.10 mg/ml) (0.10 mg/ml) (0.10 mg/ml) (0.03 mg/ml) (0.03 mg/ml) (0.03 mg/ml) (0.03 mg/ml) (0.03 mg/ml) (0.03 mg/ml) (0.1 mg/ml) 6 doses/Vial 7 doses/Vial 7 doses 7 dose 7 doses 7 dose 7 doses 7 dose 7 doses 7 doses 7 dose 7 dose 7 doses 7 dose 7	Formulations	XBB.1.5		Omicron XBB.1.5	Omicron XBB.1.5	Omicron XBB.1.5					
Coral Blue labe Maroon label border Blue label border Grey label boarder	Vaccine Type	mRNA Monovalent		mRNA Monovalent	mRNA Monovalent	mRNA Monovalent					
Multidose Multidose Multidose (0.10 mg/ml) (0.10 mg/ml) (0.015mg/ml) (0.015mg/ml) (0.033mg/ml) (0.1mg/ml) (0.1mg/ml) (0.015mg/ml) (0.033mg/ml) (0.1mg/ml) (0.1m	Cap and Label	Royal Blue cap		Maroon cap	Blue cap	Grey cap					
Authorized Age Group	Colour	Coral Blue label		Maroon label border	Blue label border	Grey label boarder					
10 doses/vial 5 doses/vial 10 doses after dilution 6 doses/Vial 7 doses 12 years and older 7 doses 12 years and older 7 doses 10 dose	Formats	Multidose	Multidose	Multidose	Multidose	Multidose					
Authorized Age Group Dose and Volume O.25ml O.5ml O.5mcg Dilution Routine schedule Authorized (or primary series complete) If primary series complete, the recommended interval is 6 months for any previously vaccinated (primary series complete) If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses. A prescription is required for the additional doses. Date Authorized O.25ml O.2ml O.3ml O	available	, ,	(0.10 mg/ml)	, ,	, ,	ν, ο,					
Dose and Volume 0.25ml 0.5ml 0.2ml 0.2ml 0.3ml		10 doses/vial	5 doses/vial	10 doses after dilution	6 doses/Vial	6 doses/Vial					
Dose and Volume 2.5 mcg 0.5 ml 50 mcg 3 mcg 10 mcg 30 mcg	Authorized Age	6 months to 11 years	12 years and older	6 Months to 4 years	5 years to 11 years	12 years and older					
Dilution None Product Source	•										
Dilution None 2.2ml/vial none None None Routine schedule	Dose and Volume										
Routine schedule *1 or 2 doses *1-3 doses 2 doses: 6m to 4 years of age and previously not vaccinated with second dose at least 4 weeks after the first dose. 3 doses: 6m to 4 years of age and previously not vaccinated with second dose at least 4 weeks after the first, followed by a third dose at least 3 weeks after the second dose. 1 dose: 5 to 11 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously vaccinated (primary series complete) 1 dose: 5 to 11 years old and previously vaccinated (primary series complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not complete) 1 dose: 5 to 11 years old and previously not vaccinated (primary series not not not previously not		25 mcg	50 mcg		10mcg	30mcg					
2 doses: 6m to 4 years of age and previously not vaccinated with second dose at least 4 weeks after the first dose. 1 dose: ≥5 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 f primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 more and previously vaccinated (primary series not complete) 1 f primary series not complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. 1 f primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023	Dilution	None		2.2ml/vial	none	None					
vaccinated with second dose at least 4 weeks after the first dose. 1 dose: ≥5 years old and previously not vaccinated with second dose at least 3 weeks after the first, followed by a third dose at least 8 weeks after the first, followed by a third dose at least 8 weeks after the first, followed by a third dose at least 8 weeks after the second dose. 1 dose: ≥5 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 dose: 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. 1 f primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023	Routine schedule	*1 or 2 doses									
after the first dose. 1 dose: ≥5 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 fprimary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. 1 fprimary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023			· · · · · · · · · · · · · · · · · · ·		•	•					
the first, followed by a third dose at least 8 weeks after the second dose. 1 dose: 5 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 frimary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. 1 frimary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-COV-2 infection (whichever is later). ★For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023				· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· — ·					
least 8 weeks after the second dose. 1 dose: ≥5 years old and previously not vaccinated (or primary series not complete) 1 dose: 6 months and older and previously vaccinated (primary series complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) 1 f primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. 1 f primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023		after the first dose.			primary series not complete)	primary series not complete)					
vaccinated (or primary series not complete) 1 dose: 6 months to 4 years and previously vaccinated (primary series complete) If primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-COV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023		1 doso: >E years old and proviously not		· · · · · · · · · · · · · · · · · · ·	1 dose: 5 to 11 years old and	1 dose: >12 years old and					
1 dose: 6 months and older and previously vaccinated (primary series complete) If primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023				reast o weeks after the second dose.		•					
1 dose: 6 months and older and previously vaccinated (primary series complete) If primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 Product		,,	, , , , , , , , , , , , , , , , , , , ,	1 dose: 6 months to 4 years and							
If primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 For links to the Covid-19 vaccine product monographs and resources refer to:		1 dose: 6 months and older and previously			,	. ,					
least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 For links to the Covid-19 vaccine product monographs and resources refer to:		vaccinated (primary series	complete)	complete)							
least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 For links to the Covid-19 vaccine product monographs and resources refer to:											
least 3 months from any previous COVID-19 vaccine formulation or known infection. If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023 For links to the Covid-19 vaccine product monographs and resources refer to:		If primary series complete, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at									
If primary series not complete, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later). *For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history, and individual circumstances. A prescription is required for the additional doses. Date Authorized Sept. 12, 2023 Sept. 28, 2023 Sept. 28, 2023 Sept. 28, 2023			,								
vaccination history, and individual circumstances. A prescription is required for the additional doses.Date AuthorizedSept. 12, 2023Sept. 28, 2023Sept. 28, 2023Sept. 28, 2023ProductFor links to the Covid-19 vaccine product monographs and resources refer to:		If primary series not co		<i>.</i> .							
Date AuthorizedSept. 12, 2023Sept. 28, 2023Sept. 28, 2023Sept. 28, 2023ProductFor links to the Covid-19 vaccine product monographs and resources refer to:		*For moderately t									
Product For links to the Covid-19 vaccine product monographs and resources refer to:		vaccination history, and individual circumstances. A prescription is required for the additional doses.									
· · · · · · · · · · · · · · · · · · ·	Date Authorized	Sept. 12,	2023	Sept. 28, 2023	Sept. 28, 2023	Sept. 28, 2023					
· · · · · · · · · · · · · · · · · · ·	Product	For links to the Covid-19 vaccine product monographs and resources refer to:									
	Monographs	Province of Manitoba Information for Health Care Professionals (gov.mb.ca)									



Influenza and Pneumococcal Vaccines Approved for Use in Canada

			1		
Formulations	Fluzone ®	FluLaval® Tetra	Alfuria ® Tetra	Fluzone ® High Dose	Pneumovax ®23
	Quadrivalent				(Pneu-P-23)
Vaccine Type	IIV4-SD	IIV4-SD	IIV4-SD	IIV4-HD	Pneumococcal
					polysaccharide 23-valent
Formats	0.5 mL single dose	5.0 mL multidose vial	0.5 mL single dose	0.7 ml Single dose prefilled	0.5 ml single dose
Available	prefilled syringe	(10 doses/vial)	prefilled syringe	syringe	prefilled syringe
	or		or		or
	5.0 mL multidose vial		5.0 mL multidose vial		0.5 ml single dose vial
	(10 doses/vial)		(10 doses/vial)		
Authorized	6 months and older	6 months and older	5 years and older	65 years and older	**65 years and older
Age Group					
Injection	0.5ml	0.5ml	0.5ml	0.7ml	0.5ml
Volume					
Dose Schedule	*1 or 2 doses:	*1 or 2 doses: children	*1 or 2 doses: children	1 dose	1 dose
	children 6 months to	6 months to less than 9	5 years to less than 9		
	less than 9 years	years	years		
	1 dose: ≥ 9 years	1 dose: ≥ 9 years	1 dose: ≥ 9 years		
Product	Fluzone PM	FluLaval PM	Afluria PM	High Dose PM	Pnuemo PM
Monograph					

^{*} Children 6 months to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.

^{**} Certain high risk criteria is required for those under 65 years of age to be eligible: visit www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.keep.html for more information